{"name":"Research Maatschap Cardiologen Rotterdam Zuid","slug":"research-maatschap-cardiologen-rotterdam-zuid","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Prasugrel based short DAPT","genericName":"Prasugrel based short DAPT","slug":"prasugrel-based-short-dapt","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Prasugrel based standard DAPT","genericName":"Prasugrel based standard DAPT","slug":"prasugrel-based-standard-dapt","indication":"Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI)","status":"marketed"}]}],"pipeline":[{"name":"Prasugrel based short DAPT","genericName":"Prasugrel based short DAPT","slug":"prasugrel-based-short-dapt","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prasugrel based standard DAPT","genericName":"Prasugrel based standard DAPT","slug":"prasugrel-based-standard-dapt","phase":"marketed","mechanism":"Prasugrel is a P2Y12 platelet receptor antagonist that irreversibly inhibits platelet aggregation as part of dual antiplatelet therapy (DAPT).","indications":["Acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI)","Reduction of thrombotic cardiovascular events in patients with ACS"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}